Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session

Published 27/03/2023, 11:37
Updated 27/03/2023, 12:40

Benzinga - U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

  • First Republic Bank (NYSE: FRC) shares jumped 25.5% to $15.51 in pre-market trading. U.S. authorities plan to give First Republic Bank more time to ramp up its balance sheet and have yet to decide on what support, if any, to provide to the troubled lender, according to Bloomberg.
  • Blackbaud, Inc. (NASDAQ: BLKB) shares rose 15% to $66.49 in pre-market trading. Clearlake Capital Group said on Mar. 24, it delivered letter to Blackbaud's board, which contained non-binding proposal.
  • Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) climbed 8.6% to $6.01 in pre-market trading. Iovance Biotherapeutics completed Biologics License Application submission for Lifileucel in advanced melanoma.
  • BridgeBio Pharma, Inc. (NASDAQ: BBIO) surged 8.3% to $16.15 in pre-market trading. BridgeBio is said to attract interest from pharma companies, according to Bloomberg.
  • PacWest Bancorp (NASDAQ: PACW) shares gained 7.9% to $10.30 in pre-market trading. Pacwest Bancorp said, consistent with its announcement on March 17, 2023, the bank continues to benefit from solid liquidity and stabilized deposit balances, with over $11.4 billion in available cash as of March 20, 2023, which exceeds total uninsured deposits of $9.5 billion as of March 20, 2023.

Don’t forget to check out our premarket coverage here

  • Novartis AG (NYSE: NVS) surged 7.1% to $89.53 in pre-market trading after the company disclosed positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) at risk of recurrence.
  • KeyCorp (NYSE: KEY) climbed 6.3% to $12.61 in pre-market trading. Citigroup upgraded KeyCorp from Neutral to Buy and announced a $20 price target.
  • Qurate Retail, Inc. (NASDAQ: QRTEA) climbed 6% to $0.8943 in pre-market trading.
  • Zions Bancorporation, National Association (NASDAQ: ZION) rose 3.3% to $29.18 in pre-market trading.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Now Read This: Investor Fear Increases Amid Recent Bank Concerns

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.